Topas Therapeutics GmbH

Topas emerges from the neuro portfolio of Bionamics GmbH which was acquired by Evotec in March 2014 and is an early stage therapeutics company using ground breaking nanoparticle technology to target autoimmune and inflammatory diseases via the induction of antigen specific immune tolerance in the liver.